P. Bonniaud (Dijon, France), E. Garrido-Martin (Madrid, Spain)
Late Breaking Abstract - Extracellular Nicotinamide Phosphoribosyltransferase (eNAMPT) is a biologic therapeutic target in preclinical and human radiation pneumonitis (RP).
A. Garcia (Tucson, United States of America), D. Valera (Tucson, United States of America), R. Oita (Tucson, United States of America), L. Moreno-Vinasco (Tucson, United States of America), N. Casanova (Tucson, United States of America), J. Garcia (Tucson, United States of America)
|    |
LSC - 2019 - Assessment of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio as biomarkers of steroid resistance in patients with COPD
A. Kadushkin, A. Tahanovich, A. Arabey, L. Shishlo, A. Savchanka, L. Movchan
| |
A study of the airway mycobiome in COPD patients and controls
E. Martinsen (Bergen, Norway), T. Eagan (Bergen, Norway), E. Leiten (Bergen, Norway), I. Haaland (Bergen, Norway), G. Husebø (Bergen, Norway), W. Sanseverino (Barcelona, Spain), A. Paytuvi-Gallart (Barcelona, Spain), R. Nielsen (Bergen, Norway)
| |
Cigarette smoking altered gut microbiota in a mouse model: the microbial lung-gut axis
W. Xiao (Chengdu, China), J. Fu (Chengdu, China), T. Miao (Chengdu, China), B. Mao (Chengdu, China)
| |
The selection of candidate microRNA biomarkers of acquired drug resistance in the lung adenocarcinoma cells treated with EGFR TKI
A. Szpechcinski (Warsaw, Poland), M. Florczuk (Warsaw, Poland), S. Rudzinski (Warsaw, Poland), D. Giedronowicz (Warsaw, Poland), R. Langfort (Warsaw, Poland), J. Chorostowska-Wynimko (Warsaw, Poland)
| |
Overexpression of LincR-PICALM promotes lung cancer proliferation and metastasis by miR-199a-3p suppression and cis- regulation
Z. Chen (Nanjing, China), M. Huang (Nanjing, China), N. Ji (Nanjing, China), M. Zhang (Nanjing, China)
| |
Chaperone-Mediated Autophagy-Dependent Chemoresistance in Non-Small Cell Lung Cancer
A. Ichikawa (Tokyo, Japan), Y. Fujita (Tokyo, Japan), Y. Hosaka (Tokyo, Japan), T. Kadota (Tokyo, Japan), A. Ito (Tokyo, Japan), T. Nakano (Tokyo, Japan), N. Saito (Tokyo, Japan), M. Yoshida (Tokyo, Japan), S. Minagawa (Tokyo, Japan), T. Numata (Tokyo, Japan), H. Hara (Tokyo, Japan), T. Ochiya (Tokyo, Japan), J. Araya (Tokyo, Japan), Y. Kaneko (Tokyo, Japan), K. Kuwano (Tokyo, Japan)
| |
Is Fezakinumab, an anti-IL22 antibody, a putative novel therapy for a subset of severe asthma?
Y. Badi (London, United Kingdom), A. Pavel (New York, United States of America), J. Riley (Stevenage, United Kingdom), K. Chung (London, United Kingdom), E. Guttman-Yassky (New York, United States of America), I. Adcock (London, United Kingdom)
| |